Get the Stockscreener App
2.11
1.86%
-0.04
After Hours:
2.03
-0.08
-3.79%
Enveric Biosciences Inc stock is traded at $2.11, with a volume of 914.64K.
It is down -1.86% in the last 24 hours and up +15.93% over the past month.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.
See More
Previous Close:
$2.15
Open:
$1.99
24h Volume:
914.64K
Relative Volume:
0.24
Market Cap:
$4.19M
Revenue:
-
Net Income/Loss:
$-8.22M
P/E Ratio:
-0.0772
EPS:
-27.3467
Net Cash Flow:
$-8.01M
1W Performance:
-16.27%
1M Performance:
+15.93%
6M Performance:
-63.87%
1Y Performance:
-87.07%
1-Day Range:
$1.86
$2.14
1-Week Range:
$1.86
$2.64
52-Week Range:
$1.71
$17.64
Enveric Biosciences Inc Stock (ENVB) Company Profile
Name
Enveric Biosciences Inc
Sector
Industry
Phone
(617) 444-8400
Address
245 FIRST STREET RIVERVIEW II 18TH FLOOR, CAMBRIDGE
Compare ENVB vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENVB
Enveric Biosciences Inc
|
2.11 | 4.27M | 0 | -8.22M | -8.01M | -27.35 |
VRTX
Vertex Pharmaceuticals Inc
|
434.31 | 110.81B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
630.30 | 66.02B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
797.77 | 48.27B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.30 | 38.22B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
147.30 | 30.69B | 742.00K | -1.37B | -1.07B | -7.0731 |
Enveric Biosciences Inc Stock (ENVB) Latest News
Enveric Biosciences Reports Positive Preclinical Results from Phototoxicity Analysis for Lead Neuroplastogen Candidate EB-003 - Investing News Network
Enveric Biosciences (ENVB) Achieves Key Milestone in Neuropsychi - GuruFocus
Enveric Biosciences Reports Financial Results and Provides Corporate Update for First Quarter 2026 - BioSpace
Enveric Biosciences Inc (ENVB) Stock Price, Quote, News & History - Benzinga
Enveric Biosciences (ENVB) affiliates report 158,732 warrants; Easton 161,232 - Stock Titan
Enveric (ENVB) Secures $13.9 Million in Private Placement Fundin - GuruFocus
Enveric (ENVB) Advances in Mental Health Therapeutics Developmen - GuruFocus
Enveric Biosciences Reports Q1 2026 Results, Advances Non-Hallucinogenic Antidepressant EB-003 Toward Clinical Trials - Minichart
Enveric Biosciences Releases Q1 2026 Financial Results - AlphaStreet
Enveric Biosciences (NASDAQ: ENVB) posts Q1 2026 loss and flags going concern risk - Stock Titan
Enveric Biosciences (ENVB) advances EB-003 and boosts cash in Q1 2026 - Stock Titan
What's going on with Enveric Biosciences stock on Friday? - MSN
Enveric Biosciences Expands IP Portfolio with New U.S. Patent Issued for Methods of Treating Psychiatric Disorders - Investing News Network
Enveric highlights preclinical PTSD data amid rising focus on mental health therapies - MSN
Enveric Biosciences receives patent for psilocybin derivatives By Investing.com - Investing.com Canada
Enveric Biosciences (ENVB) Expands Patent Portfolio with New Psi - GuruFocus
Enveric Biosciences Stock Short Interest Rises to 45.7% - Moomoo
TradingKey - TradingKey
MSN Money - MSN
Enveric Biosciences Inc. (ENVB) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
ENVB Stock Price, Quote & Chart | ENVERIC BIOSCIENCES INC (NASDAQ:ENVB) - ChartMill
Enveric Biosciences Highlights Positive Results for EB-003 in PTSD Preclinical Model - Investing News Network
Enveric Biosciences IncReports positive preclinical results for EB-003 in PTSD model - marketscreener.com
Enveric Highlights Preclinical PTSD Data Amid Rising Focus On Mental Health TherapiesEnveric Bioscienc - Benzinga
Enveric Biosciences surges over 90%, other psychedelic stocks soar in Monday pre-market: What's going on? - MSN
Enveric Biosciences Corrects Reverse Stock Split Proxy Disclosure - TipRanks
Enveric Biosciences (ENVB) clarifies 1‑for‑15 max reverse split in 2026 proxy - Stock Titan
Enveric Biosciences | EFFECT: Others - Moomoo
Enveric Biosciences (NASDAQ: ENVB) files resale prospectus for 6.82M shares - Stock Titan
Lakewood-Amedex appoints Enveric CEO to board of directors - Investing.com UK
Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors - Investing News Network
Lakewood-Amedex appoints Enveric CEO to board of directors By Investing.com - Investing.com Nigeria
Enveric Biosciences Inc Stock (ENVB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.19%
0.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):